Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Natural killer cells

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44380   clinical trials with a EudraCT protocol, of which   7392   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    48 result(s) found for: Natural killer cells. Displaying page 3 of 3.
    « Previous 1  2  3 
    EudraCT Number: 2009-017432-40 Sponsor Protocol Number: MGN1703-C02 Start Date*: 2010-04-13
    Sponsor Name:MOLOGEN AG
    Full Title: A Phase 2, Randomized, Double-blind, Placebo-controlled, Multi-Center Clinical Study to Evaluate Efficacy and Safety of a Maintenance Therapy with Immunomodulator MGN1703 in Patients with Advanced ...
    Medical condition: Patients with advanced colorectal carcinoma (AJCC Stage IV) with disease control after initial first-line therapy
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10010036 Colorectal carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Prematurely Ended) GB (Completed) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-007057-42 Sponsor Protocol Number: A4M108119 Start Date*: 2007-05-29
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: An open-label study of leukocyte counts in the cerebrospinal fluid and blood of subjects with relapsing forms of multiple sclerosis following treatment with firategrast
    Medical condition: relapsing forms of multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063399 Relapsing-remitting multiple sclerosis LLT
    9.1 10063400 Secondary progressive multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) SE (Completed) CZ (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2011-000847-25 Sponsor Protocol Number: EMR63325-013 Start Date*: 2011-07-04
    Sponsor Name:Merck KGaA
    Full Title: A multi-center, randomized, open-label, mechanism of action trial on the biological effects of the therapeutic cancer vaccine Stimuvax® (L-BLP25) in rectal cancer subjects undergoing neoadjuvant ch...
    Medical condition: Rectal cancer subjects undergoing neoadjuvant chemoradiotherapy
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10038043 Rectal cancer Duke's C LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) PT (Completed) DE (Completed) NL (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2014-000382-41 Sponsor Protocol Number: WA29330 Start Date*: 2015-03-06
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A randomized, double-blind, double-dummy active-comparator, multicenter study to evaluate the efficacy and safety of rituximab versus MMF in patients with pemphigus vulgaris
    Medical condition: Pemphigus Vulgaris (PV)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10052802 Pemphigus vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) IT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-001468-23 Sponsor Protocol Number: TG4010.14 Start Date*: 2011-12-19
    Sponsor Name:Transgene S.A.
    Full Title: A Phase IIb/III randomized, double-blind, placebo-controlled study comparing first-line therapy with or without TG4010 immunotherapy product in patients with stage IV non-small cell lung cancer (NS...
    Medical condition: Stage IV non small cell lung cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10025055 Lung cancer non-small cell stage IV LLT
    19.0 100000004864 10025048 Lung cancer non-small cell recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) HU (Completed) GB (Completed) DE (Prematurely Ended) ES (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-012083-14 Sponsor Protocol Number: EPC2008-02 Start Date*: 2009-06-17
    Sponsor Name:MEDA Pharma GmbH & Co. KG
    Full Title: An Open-Label, Multicenter Study of the Effects of Remission Maintenance Therapy with Ceplene® (Histamine Dihydrochloride), Given in Conjunction with Low-Dose Interleukin-2 (IL-2, Proleukin®), on I...
    Medical condition: Acute Myeloid Leukemia in First Complete Remission (CR1)
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10000887 Acute myeloid leukemia in remission LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) BE (Prematurely Ended) GB (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2009-018077-31 Sponsor Protocol Number: 012010 Start Date*: 2010-11-25
    Sponsor Name:St. Anna Kinderkrebsforschung/CCRI
    Full Title: A PHASE I/II DOSE SCHEDULE FINDING STUDY FOR CH14.18/CHO CONTINUOUS INFUSION COMBINED WITH SUBCUTANEOUS ALDESLEUKIN (IL-2) IN PATIENTS WITH PRIMARY REFRACTORY OR RELAPSING NEUROBLASTOMA
    Medical condition: High-risk neuroblastoma patients having received at least one previous high dose treatment followed by stem cell rescue after conventional therapy fulfilling one of the following criteria: • Prima...
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: AT (Completed) ES (Ongoing) DE (Completed) IT (Ongoing) GB (GB - no longer in EU/EEA) IE (Completed) PL (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-002117-28 Sponsor Protocol Number: ACE-LY-004 Start Date*: 2015-05-06
    Sponsor Name:Acerta Pharma B.V.
    Full Title: An Open-label, Phase 2 Study of ACP-196 in Subjects with Mantle Cell Lymphoma
    Medical condition: Mantle Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10026798 Mantle cell lymphomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) BE (Completed) CZ (Completed) ES (Ongoing) IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3 
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Feb 12 10:41:38 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA